These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 14278335)

  • 1. COMPARISON OF THYMINALKYLAMINE AND ENDOXAN EFFECT ON ADVANCED GYNECOLOGICAL CARCINOMAS IN A CONTROLLED CLINICAL TRIAL.
    DVORAK O; ELIS J; JELINEK J; KAFKA V; MUSIL J; SCHUBERT J
    Neoplasma; 1965; 12():87-91. PubMed ID: 14278335
    [No Abstract]   [Full Text] [Related]  

  • 2. [CYTOLOGICAL CHANGES IN ASCITIC AND PLEURAL PUNCTATES IN ADVANCED GYNECOLOGICAL CANCER FOLLOWING CYTOSTATIC THERAPY WITH ENDOXAN AND MEBRYL].
    DVORAK O; VENTA J
    Cesk Gynekol; 1964 Feb; 29():79-82. PubMed ID: 14142675
    [No Abstract]   [Full Text] [Related]  

  • 3. A controlled clinical trial with the cytostatic agent thyminalkylamine and its fluorinated derivative on advanced ovarian tumours.
    Dvorák O; Elis J; Perlík F; Kvícalová M; Jandová A; Skoda V; Kafka V
    Neoplasma; 1971; 18(4):365-9. PubMed ID: 5568931
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of effects of cyclophosphamide, Cytembena, and Ypenyl in the treatment of inoperable ovarian carcinoma.
    Skoda V; Elis J; Jandová A; Laurová L; Novotná J; Perlík F
    Neoplasma; 1971; 18(5):471-2. PubMed ID: 5165867
    [No Abstract]   [Full Text] [Related]  

  • 5. [Experiences on in vitro testing of cytostatic sensitivity (oncobiogram) in gynecological tumors].
    Krafft W; Preibsche W; Marzotko F
    Arch Geschwulstforsch; 1973; 41(3):241-7. PubMed ID: 4732846
    [No Abstract]   [Full Text] [Related]  

  • 6. [Studies on the concentration of cyclophosphamide (Endoxan) in the blood and tissues in patients with gynecological cancer, with special reference to optimum dosage].
    Tashiro K
    Gan No Rinsho; 1969 Apr; 15(4):433-8. PubMed ID: 5817055
    [No Abstract]   [Full Text] [Related]  

  • 7. NITROGEN MUSTARD-RESISTANT YOSHIDA SARCOMA AND CROSS-RESISTANCE STUDIES.
    UJHAZY V; WINKLER A
    Neoplasma; 1965; 12():11-4. PubMed ID: 14278323
    [No Abstract]   [Full Text] [Related]  

  • 8. [CHEMOTHERAPY OF UTERINE CERVIX CARCINOMA].
    PERITI P; MAIJNELLI M
    Riv Ostet Ginecol; 1964 Jan; 19():56-60. PubMed ID: 14165768
    [No Abstract]   [Full Text] [Related]  

  • 9. CHEMOTHERAPY OF BREAST CANCER.
    SILVA AR; SMART CR; ROCHLIN DB
    Surg Gynecol Obstet; 1965 Sep; 121():494-8. PubMed ID: 14332883
    [No Abstract]   [Full Text] [Related]  

  • 10. [A study of the effect of endoxan on the serum cholinesterase activity in gynecologic carcinomas].
    Dacić Z
    Zentralbl Gynakol; 1965 Sep; 87(37):1249-56. PubMed ID: 5884968
    [No Abstract]   [Full Text] [Related]  

  • 11. A comparison between the hematological side effects of cyclophosphamide and nitrogen mustard.
    NISSEN-MEYER R; HOST H
    Cancer Chemother Rep; 1960 Nov; 9():51-5. PubMed ID: 13729268
    [No Abstract]   [Full Text] [Related]  

  • 12. [MEDULLARY APLASIA DURING THE USE OF 4 ANTIMITOTICS: CARYOLYSIN, MYLERAN, THIOTEPA, ENDOXAN (APROPOS OF 32 CASES)].
    PLAUCHU M; DALMAIS J; GUINGAND M
    J Med Lyon; 1963 Dec; 44():1811-65. PubMed ID: 14126897
    [No Abstract]   [Full Text] [Related]  

  • 13. CLOSED PELVIC PERFUSION: A NEW APPROACH TO THE PROBLEM OF ADVANCED GYNECOLOGIC MALIGNANCY.
    CAVANAGH D; MARTIN DS; HERNANDEZ-ROMAN P
    Am J Obstet Gynecol; 1965 Aug; 92():996-1005. PubMed ID: 14321117
    [No Abstract]   [Full Text] [Related]  

  • 14. THE TREATMENT OF CARCINOMA IN DOGS' BLADDERS WITH CYTOTOXIC DRUGS.
    BOYLAND E; KINDER CH; WILLIAMS K
    Invest Urol; 1965 Mar; 2():446-52. PubMed ID: 14261785
    [No Abstract]   [Full Text] [Related]  

  • 15. [Ist clinical trials of a new nitrogen mustard, cyclophosphamide or Endoxan].
    LAMARQUE P; ROMIEU C; GARY-BOBO J; POURQUIER H; PUJOL H; BELOTTE J; DOSSA J; JAFFIOL C; LAMARQUE JL
    Sem Hop Ther Paris; 1961 Nov; 37():839-40. PubMed ID: 14461708
    [No Abstract]   [Full Text] [Related]  

  • 16. [Clinical experiences with the cyclic nitrogen mustard phosphamide ester, Endoxan in the treatment of malignant tumors].
    SCHARENBERG P; KAPISCHKE F
    Munch Med Wochenschr; 1962 Jan; 104():134-8. PubMed ID: 14498052
    [No Abstract]   [Full Text] [Related]  

  • 17. [Evaluation of the specificity of anti-proliferative drugs. Comparison of nitrogen mustard, triethylene melamine and cyclophosphamide].
    SCALTRINI GC; TOGNELLA S; CONIGLIARO S; GRIFONI V
    Haematol Lat; 1961; 4():411-22. PubMed ID: 14497771
    [No Abstract]   [Full Text] [Related]  

  • 18. [Our initial experience with endoxan (B 518) therapy].
    PRCIC M
    Med Arh; 1959; 13():127-41. PubMed ID: 14434709
    [No Abstract]   [Full Text] [Related]  

  • 19. [On the antineoplastic action of a cyclic phosphamide ester of nitrogen mustard (endoxan, or B 518). Clinical tests].
    DI PIETRO S
    Minerva Med; 1959 Oct; 50():3450-4. PubMed ID: 13816482
    [No Abstract]   [Full Text] [Related]  

  • 20. [CYCLOPHOSPHAMIDE IN THE TREATMENT OF TUMORS OF THE HEAD AND NECK. CONTRIBUTION TO ITS STUDY OF CONTINUOUS ARTERIAL INFUSSION].
    CAPPELLANO R
    Rev Bras Cir; 1964 Nov; 48():375-89. PubMed ID: 14260731
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.